Biology
How Biotechnology Turns DNA into Medicine
Quick fact
The first biotech drug approved by the FDA was human insulin produced in bacteria (1982), replacing insulin from pigs and cows and making it safer for millions of diabetics.
Why this is interesting
You know your body reads DNA to make proteins – but what if we could write new DNA instructions to cure disease? That's exactly how biotechnology turns DNA into medicine.
Read the full explanation
Understanding How Biotechnology Turns DNA into Medicine
Think of DNA as a recipe book for proteins. Biotechnologists identify a human gene that codes for a useful protein, like insulin. They cut that gene using enzymes and paste it into a tiny circular DNA called a plasmid, which acts as a delivery vehicle. This recombinant plasmid is inserted into a host cell, often a bacterium or yeast. The host cell, now a mini factory, reads the human gene and starts producing the insulin protein. The protein is then harvested, purified, and packaged as medicine. The same principle works for antibodies, growth factors, and enzymes.
A deeper explanation
The core mechanism is recombinant DNA technology. Restriction enzymes cut DNA at specific sequences, creating sticky ends. DNA ligase then joins the human gene to the plasmid, creating a stable recombinant molecule. The plasmid includes a selectable marker (e.g., antibiotic resistance) to isolate successfully transformed cells. Host cells are grown in large bioreactors under controlled conditions. After expression, the protein undergoes purification (chromatography) to ensure purity and activity. This process matters because it enables the production of human-identical proteins that are less likely to cause immune reactions than animal-derived ones. It also allows large-scale production that is reliable and ethical. Extensions include gene therapy, where a correct version of a gene is delivered into a patient's cells to treat genetic disorders, and monoclonal antibody production for targeted cancer therapy.